(Reuters) – Eli Lilly (NYSE:) expects to start selling its weight-loss drug in Hong Kong as early as the end of this year, Bloomberg News reported on Sunday.
The company has received the Hong Kong government approval to sell its tirzepatide injections — branded as Mounjaro — in a device called Kwikpen for both long-term weight management and type 2 diabetes, Eli Lilly told Bloomberg in a statement.
By Farah Khan The Curator Team Posted March 12, 2026 7:00 am 1 min read…
Supported in part by a growing U.S. defense budget, legacy aerospace and defense ETFs are…
An Al Jazeera crew filmed bunker-busting bombs being loaded onto US military planes at a…
Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure Following the…
Kelowna, B.C., city council is expected to vote on a controversial land swap proposal on…
NEW YORK, NY, UNITED STATES, March 10, 2026 Astoria today announces that assets under management…